TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16984719

Group type: EXPERIMENTAL
Intervention: Respect
Number of subjects: 80

Group type: COMPARATOR
Intervention: Disrespect
Number of subjects: 80
Study: 15039146

Group type: EXPERIMENTAL
Intervention: Intermittent bright light (six 15-min bright light pulses of approximately 9,500 lux separated by 60 min of very dim light of <1 lux)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Continuous bright light (approximately 9,500 lux)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Continuous very dim light (<1 lux)
Number of subjects: 21
Study: 10953262

Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 51000

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 51000

Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 51000
Study: 9054792

Group type: EXPERIMENTAL
Intervention: Debriefing intervention 6 months after disaster
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 8368410

Group type: EXPERIMENTAL
Intervention: Diclofenac, 75 mg twice daily for 3 to 5 days before and for 7 days after surgery
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Placebo preoperatively and diclofenac postoperatively
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo at both times
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 67
Study: 2872365

Group type: EXPERIMENTAL
Intervention: Linolenic acid (0%, 4%, 8%, 12%, 16% of total energy intake)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (1.7%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no linolenic acid or eicosapentaenoic acid)
Number of subjects: 12
Study: 29783962

Group type: EXPERIMENTAL
Intervention: Obesity category 2 (BMI 35 to < 40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Obesity category 3 (BMI ≥ 40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Not being employed
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Non-English speaking backgrounds
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HLQ domain: ability to actively engage with healthcare providers
Number of subjects: 120
Study: 27595147

Group type: EXPERIMENTAL
Intervention: pexacerfont (300 mg/day for 7 days, then 100 mg/day for 21 days)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: pexacerfont
Number of subjects: 31
Study: 24503451

Group type: EXPERIMENTAL
Intervention: Video group (BLS learned through videos with on‐screen instructions)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Picture group (BLS learned by means of pictures combined with written instructions)
Number of subjects: 128
Study: 22775294

Group type: EXPERIMENTAL
Intervention: 10 targeted messages
Number of subjects: 181

Group type: COMPARATOR
Intervention: 10 generic messages
Number of subjects: 181
Study: 20390343

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 706

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 706
Study: 18727024

Group type: EXPERIMENTAL
Intervention: Unipolar RF treatment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bipolar RF treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 10
Study: 16110017

Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy
Number of subjects: 304

Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy
Number of subjects: 304
Study: 12355185

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10030326

Group type: EXPERIMENTAL
Intervention: Intensive treatment (stepwise implementation of behaviour modification, pharmacological therapy targeting hyperglycaemia, hypertension, dyslipidaemia, and microalbuminuria)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard treatment (followed Danish guidelines)
Number of subjects: 160
Study: 7575052

Group type: EXPERIMENTAL
Intervention: Oral prednisolone alone
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Praziquantel with prednisolone
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Albendazole with prednisolone
Number of subjects: 138

Group type: COMPARATOR
Intervention: Symptomatic treatment alone (prednisolone)
Number of subjects: 138
Study: 2341751

Group type: EXPERIMENTAL
Intervention: High-dose human leukocyte interferon-alpha (IFN-alpha)
Number of subjects: 10
Study: 7396099

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (i.v. administered)
Number of subjects: 23
Study: 31883929

Group type: EXPERIMENTAL
Intervention: Dual tasking (lingual dual task using a smartphone app)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Recall only (without dual task)
Number of subjects: 37
Study: 31042140

Group type: EXPERIMENTAL
Intervention: Training with external attentional focus
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Training with internal attentional focus
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both groups (internal and external focus)
Number of subjects: 22
Study: 28477995

Group type: EXPERIMENTAL
Intervention: Mtwo (VDW, Munich, Germany)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Reciproc (VDW)
Number of subjects: 65
Study: 25918727

Group type: EXPERIMENTAL
Intervention: sulodexide 100 mg/day for 14 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23524361

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) only (n = 6; 28 days glucose placebo, acute NaHCO3)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Beta alanine (BA) and sodium bicarbonate (NaHCO3) (n = 6; 28 days BA, acute NaHCO3)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Beta alanine (BA) only (n = 6; 28 days BA, acute sodium chloride placebo)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo only (n = 6; 28 days glucose placebo, acute sodium chloride placebo)
Number of subjects: 24
Study: 21414453

Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging (MBB)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Active sleep education control
Number of subjects: 63
Study: 19542797

Group type: EXPERIMENTAL
Intervention: Microcurrent therapy (MCT) patch
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 10
Study: 17854237

Group type: EXPERIMENTAL
Intervention: Hydralazine capsule plus ISDN tablet (V‐HeFT I formulation)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hydralazine tablet plus ISDN tablet (V‐HeFT II formulation)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: FDC ISDN/HYD (A‐HeFT formulation)
Number of subjects: 19
Study: 15367303

Group type: EXPERIMENTAL
Intervention: Chronic pain patients
Number of subjects: 91

Group type: COMPARATOR
Intervention: Acute pain patients
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Cognitively impaired patients
Number of subjects: 91

Group type: COMPARATOR
Intervention: Cognitively less-impaired patients
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Overall pain intensity and improvement in ADL measure
Number of subjects: 91
Study: 11543695

Group type: EXPERIMENTAL
Intervention: Combination of methotrexate, sulfasalazine, and hydroxychloroquine
Number of subjects: 2221

Group type: EXPERIMENTAL
Intervention: Combination of methotrexate and cyclosporin
Number of subjects: 2221

Group type: EXPERIMENTAL
Intervention: Combination of anti-TNF therapy with methotrexate
Number of subjects: 2221

Group type: EXPERIMENTAL
Intervention: Corticosteroids in addition to the combination therapies
Number of subjects: 2221

Group type: EXPERIMENTAL
Intervention: Other combinations involving parenteral gold, penicillamine, and azathioprine
Number of subjects: 2221
Study: 9600553

Group type: EXPERIMENTAL
Intervention: Intramuscular botulinum toxin A (BtA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Serial casting
Number of subjects: 20
Study: 7973470

Group type: EXPERIMENTAL
Intervention: Psychoeducational family management with standard dose or targeted medication
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Psychoeducational family management
Number of subjects: 411
Study: 2681764

Group type: EXPERIMENTAL
Intervention: Continuous allopurinol therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intermittent allopurinol therapy (2 months every year)
Number of subjects: 50
Study: 4573357

Group type: EXPERIMENTAL
Intervention: Dip-inoculation slides used in surgery for diagnosis
Number of subjects: 4

Group type: COMPARATOR
Intervention: Laboratory incubation and interpretation of dip slides
Number of subjects: 4
Study: 29446317

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 19
Study: 27931951

Group type: EXPERIMENTAL
Intervention: 3-minute withdrawal
Number of subjects: 200

Group type: COMPARATOR
Intervention: 6-minute withdrawal
Number of subjects: 200
Study: 26502544

Group type: EXPERIMENTAL
Intervention: Acupuncture + Low Frequency Shock Wave (LFSW)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acupuncture + Medium Frequency Shock Wave (MFSW)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acupuncture + High Frequency Shock Wave (HFSW)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Routine Acupuncture
Number of subjects: 120
Study: 23951832

Group type: EXPERIMENTAL
Intervention: Smoking prevention program (2 days duration)
Number of subjects: 226
Study: 21513477

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich fibrin (PRF) with open-flap debridement
Number of subjects: 56

Group type: COMPARATOR
Intervention: Open-flap debridement alone
Number of subjects: 56
Study: 18326616

Group type: EXPERIMENTAL
Intervention: Isoflavone-enriched foods providing a mean daily intake of 110 mg isoflavone aglycones
Number of subjects: 237

Group type: COMPARATOR
Intervention: Control products
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Isoflavone-enriched foods
Number of subjects: 237
Study: 15528283

Group type: EXPERIMENTAL
Intervention: Ciclosporin A (CSA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 14740274

Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.1 IU/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Regular human insulin (0.1 IU/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insulin glargine and regular human insulin
Number of subjects: 20
Study: 10755029

Group type: EXPERIMENTAL
Intervention: Enhanced care and support
Number of subjects: 154

Group type: COMPARATOR
Intervention: Regular health services
Number of subjects: 154
Study: 8926224

Group type: EXPERIMENTAL
Intervention: Physically guiding the child to accept food contingent on noncompliance
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Nonremoval of the spoon until the child accepted the presented food
Number of subjects: 3
Study: 1299490

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (365 mg per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 20
Study: 6493927

Group type: EXPERIMENTAL
Intervention: Subjective organization (free recall in any order)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Experimenter-presented order (recall from shortest to longest)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Forced-random group (recall in the same order as presented)
Number of subjects: 60
Study: 30107419

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Combination nicotine patch and lozenge
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Patch monotherapy
Number of subjects: 1086
Study: 29935535

Group type: EXPERIMENTAL
Intervention: Intravenous propacetamol followed by oral placebo
Number of subjects: 263

Group type: COMPARATOR
Intervention: Oral dexibuprofen after intravenous 0.9% sodium chloride solution
Number of subjects: 263
Study: 26864057

Group type: EXPERIMENTAL
Intervention: Core Stability Exercise (CSE)
Number of subjects: 43

Group type: COMPARATOR
Intervention: General Exercise (GE)
Number of subjects: 43
Study: 25172878

Group type: EXPERIMENTAL
Intervention: Low-dose PAZ320 (8 g)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-dose PAZ320 (16 g)
Number of subjects: 24
Study: 22684202

Group type: EXPERIMENTAL
Intervention: Progressive Dynamic Spine Stabilization Exercise Protocols (PDSSEP) - Thoracic Group
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Progressive Dynamic Spine Stabilization Exercise Protocols (PDSSEP) - Cervical Group
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 104
Study: 20455890

Group type: EXPERIMENTAL
Intervention: Individualized GH treatment (17-100 microg/kg/day)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard GH dose treatment (43 microg/kg/day)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Individualized GH treatment
Number of subjects: 128
Study: 18592087

Group type: EXPERIMENTAL
Intervention: No-touch technique
Number of subjects: 156

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 156

Group type: COMPARATOR
Intervention: Intermediate technique
Number of subjects: 156
Study: 17663377

Group type: EXPERIMENTAL
Intervention: Thyroidectomy with LigaSure
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional thyroidectomy
Number of subjects: 50
Study: 12854177

Group type: EXPERIMENTAL
Intervention: Sea buckthorn extract, 15 g 3 times a day for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vitamin B complex one tablet, 3 times a day for 6 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sea buckthorn extract
Number of subjects: 50
Study: 10702196

Group type: EXPERIMENTAL
Intervention: Tegaserod, 2 mg twice daily for 1 week
Number of subjects: 24
Study: 9337188

Group type: EXPERIMENTAL
Intervention: ELCA+PTCA
Number of subjects: 98

Group type: COMPARATOR
Intervention: PTCA alone
Number of subjects: 98
Study: 8225212

Group type: EXPERIMENTAL
Intervention: Propranolol (0.15 mg/kg, intravenously)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 3981366

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29478970

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sitagliptin plus GHR antagonist
Number of subjects: 39
Study: 26679680

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 110

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 110
Study: 25437480

Group type: EXPERIMENTAL
Intervention: TECNIS Toric IOL
Number of subjects: 174
Study: 23242398

Group type: EXPERIMENTAL
Intervention: Hua Oranga
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: PCS (Physical Component Summary of SF36)
Number of subjects: 172
Study: 20556256

Group type: EXPERIMENTAL
Intervention: Immediate implant placement
Number of subjects: 24

Group type: COMPARATOR
Intervention: Delayed implant placement (ridge preservation with grafting)
Number of subjects: 24
Study: 18854562

Group type: EXPERIMENTAL
Intervention: Amrubicin (40 mg/m² on days 1-3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topotecan (1.0 mg/m² on days 1-5)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amrubicin (in sensitive relapse)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topotecan (in sensitive relapse)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amrubicin (in refractory relapse)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topotecan (in refractory relapse)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amrubicin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topotecan
Number of subjects: 60
Study: 15699236

Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (850 microg retinol equivalents/d)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Vitamin A-fortified rice (850 microg retinol equivalents/d)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Goat liver (850 microg retinol equivalents/d)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amaranth leaves (850 microg retinol equivalents/d)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Carrots (850 microg retinol equivalents/d)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (2000 microg retinol equivalents/d)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Liver (2000 microg retinol equivalents/d)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Vegetable groups (amaranth leaves, carrots)
Number of subjects: 6
Study: 12731456

Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg (E20)
Number of subjects: 1881

Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg (E10)
Number of subjects: 1881

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg (L10)
Number of subjects: 1881

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 1881
Study: 10569660

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/day) + placebo (E+P)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day) + placebo (L+P)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enalapril + Losartan (E+L)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo + Placebo (P+P)
Number of subjects: 20
Study: 8702449

Group type: EXPERIMENTAL
Intervention: Treatment counseling telephone intervention
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Symptom monitoring telephone intervention
Number of subjects: 405

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 405
Study: 1649715

Group type: EXPERIMENTAL
Intervention: Gliclazide (80 mg) administered 90 min before glucose clamp
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (without gliclazide)
Number of subjects: 8
Study: 6482180

Group type: EXPERIMENTAL
Intervention: Bicarbonate hemodialysis under low-sodium conditions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acetate hemodialysis under low-sodium conditions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acetate hemodialysis under high-sodium conditions
Number of subjects: 12
Study: 30447037

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 56
Study: 30318893

Group type: EXPERIMENTAL
Intervention: Propofol (average up to 115 mg in boluses of 20 mg) plus placebo (saline solution)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Midazolam (3 mg) plus propofol (average up to 83 mg in boluses of 20 mg)
Number of subjects: 83
Study: 27095338

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and Cognitive Behavioral Therapy (MICBT) plus standard care
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Longer term MICBT plus standard care
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 35
Study: 25429129

Group type: EXPERIMENTAL
Intervention: Targeted memory reactivation (TMR) of specific memory traces during slow-wave sleep
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving TMR before sleep
Number of subjects: 0
Study: 22759200

Group type: EXPERIMENTAL
Intervention: Generic tacrolimus (Sandoz)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Reference tacrolimus (Prograf®)
Number of subjects: 71
Study: 21162951

Group type: EXPERIMENTAL
Intervention: Tourniquet applied during total knee arthroplasty
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no tourniquet)
Number of subjects: 60
Study: 17707851

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 microg/(kg min) for 24 hours, n=26)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (n=13)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 16809734

Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Number of subjects: 127

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 127
Study: 11893228

Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs (AEDs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Old antiepileptic drugs (AEDs)
Number of subjects: 0
Study: 10458941

Group type: EXPERIMENTAL
Intervention: Writing task (motor activation)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Supine resting state (control)
Number of subjects: 26
Study: 7610938

Group type: EXPERIMENTAL
Intervention: Alendronate 20 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2514782

Group type: EXPERIMENTAL
Intervention: Spiramycin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 55
Study: 832830

Group type: EXPERIMENTAL
Intervention: Migraeflux
Number of subjects: 32
Study: 29784556

Group type: EXPERIMENTAL
Intervention: Classical Turkish music
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 30
Study: 28240966

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (CBT)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 169
Study: 24861978

Group type: EXPERIMENTAL
Intervention: 100% autologous bone (Group A)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100% porcine bone (Group B)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 50 : 50 mixture of autologous and porcine bone (Group C)
Number of subjects: 10
Study: 23574990

Group type: EXPERIMENTAL
Intervention: Classical music intervention (1 hour in the waiting area with classical music in the background)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (1 hour with no music)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Classical music intervention
Number of subjects: 169
Study: 21269858

Group type: EXPERIMENTAL
Intervention: Single 60‐mg/kg dose of azithromycin extended‐release (ER)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10‐day regimen of amoxicillin/clavulanate 90/6.4 mg/kg per day
Number of subjects: 0
Study: 19384185

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) used as an early drug in a calcineurin inhibitor-free protocol in the first 3 months after transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) used in early and late conversion protocols as suggested by the multicenter randomized CONVERT trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) used in recipients from marginal donors
Number of subjects: 0